It may also be reasonable to switch patients requiring high doses of UFH to one of the direct thrombin inhibitors (DTI) e.g., Argatroban or Bivalirudin, that act independently of ATIII, and do not cause immune-mediated thrombocytopaenia. The gene discussed is SERPINC1; the disease is Thrombocytopenia.